

# CARN-AP Resources

Last Updated February 18<sup>th</sup>, 2025

## **DISCLAIMER:**

The resources provided are study tools to help you prepare for the CARN-AP Exam. Using these resources to prepare for the CARN-AP certification examination does not guarantee a passing score on the certification exam.

## **Text-based Resources**

1. American Psychiatric Association (2022). *Diagnostic and statistical manual of mental disorders* (5th ed., text rev.; DSM-5-TR) Washington, DC: American Psychiatric Publishing.
2. Stahl S.M. (2024). *Prescriber's Guide: Stahl's Essential Psychopharmacology*, 8th ed., Cambridge University Press.
3. Black, D. W. (2007). A review of compulsive buying disorder. *World Psychiatry*, 6(1), 14–18.
4. Herron, A.J., Brennan, T.K. (2020). *The ASAM Essentials of Addiction Medicine*, 3rd ed., Philadelphia: Wolters Kluwer.
5. Lexicomp (2018). *Drug Information Handbook for Advanced Practice Nursing*, 17th ed., Philadelphia: Wolters Kluwer
6. Miller, S. C., Levy, S., Rosenthal, R. N., Saxon, A. J., Tetrault, J. M., Wakeman, S. E., & American Society of Addiction Medicine (Eds.) (2024). *The ASAM Principles of Addiction Medicine*, 7th ed., Philadelphia: Wolters Kluwer.
7. Miller, W. R., & Rollnick, S. (2018). *Motivational interviewing: Helping people change* (3rd ed.). The Guilford Press.
8. Morgan, K.I., Townsend, M.C. (2020). *Essentials of Psychiatric Mental Health Nursing*, 8<sup>th</sup> ed., Philadelphia: F.A. Davis.
9. Perry, P. J., Alexander, B., Liskow, B., & DeVane, C. L. (2007). *Psychotropic drug handbook* (8th ed.). Lippincott Williams & Wilkins.
10. Sadock, B.J., Ahmad, S., Sadock, V.A. (2018). *Pocket Handbook of Clinical Psychiatry*, 7<sup>th</sup> ed., Philadelphia: Wolters Kluwer.
11. Shields, K.M, Kami, L.F, Liebrecht, C. (2020). *Pearson Nurse's Drug Guide 2020*. Hoboken, NJ: Pearson.

## Video Resources

1. Boston Medical Center's Grayken Center for Addiction Training & Technical Assistance (2023, December). *Pharmacodynamics of medications for opioid use disorder* [Video]. YouTube. <https://www.youtube.com/watch?v=GftLdCSi9bA>
2. Boston Medical Center's Grayken Center for Addiction Training & Technical Assistance (2024, December). *Buprenorphine Extended-Release Injection: An Instructional Guide* [Video]. YouTube. <https://www.youtube.com/watch?v=cBNLabyxNbM&t=1s>
3. Boston Medical Center's Grayken Center for Addiction Training & Technical Assistance (2024, July). *Overdose prevention: Reviewing different naloxone formulations* [Video]. YouTube. <https://www.youtube.com/watch?v=BNGpUkhujk&list=PLoNCse8rBBDCEDDZTwTDve9zS0eZyO-5a&index=11>
4. Boston Medical Center's Grayken Center for Addiction Training & Technical Assistance (2020, November). *Medications for Treatment of Alcohol Use Disorder* [Video]. YouTube. <https://www.youtube.com/watch?v=6anZ3XGG-gE>
5. Boston Medical Center's Grayken Center for Addiction Training & Technical Assistance (2020, September). **Common Dilemmas in the Ethical Treatment of Inpatients with Substance Use Disorders** [Video]. YouTube. <https://www.youtube.com/watch?v=5eIEBNxN8pA>
6. \*\*Several additional, short resource videos are available at <https://www.addictiontraining.org/resources/?category=8>

## Web-based Resources

- [American Society of Addiction Medicine](#)
- [Substance Abuse & Mental Health Services Administration](#)
  - [Treatment Improvement Protocols \(TIPS\)](#)
- [Centers for Disease Control & Prevention](#)
- [Food & Drug Administration](#)
- [Drug Enforcement Administration](#)
- [John Hopkins Medicine](#)
- [CDC National Center for Health Statistics](#)
- [National Center for PTSD](#)
- [National Council for Mental Wellbeing](#)
- [National Harm Reduction Coalition](#)
- [National Institute on Alcohol Abuse & Alcoholism](#)
- [National Institute on Drug Abuse](#)
- [Sexual Medicine Society of North America](#)
- [UCLA Gambling Studies Program](#)
- [United Nations Office on Drugs & Crime](#)

1. Addictions Nursing Certification Board (2023, March). *CARN-AP certification handbook & application*.  
[https://www.cnetnurse.com/\\_files/ugd/8331ae\\_cd2c735e298f48b7b506ad68dc71fd47.pdf](https://www.cnetnurse.com/_files/ugd/8331ae_cd2c735e298f48b7b506ad68dc71fd47.pdf)
2. Massachusetts Department of Public Health Bureau of Substance Abuse Services (2016, March). Standards of care. <https://www.mass.gov/doc/dph-bureau-of-substance-abuse-services-standards-of-care/download>
3. National Council of State Boards Nursing (2018). *A Nurses Guide to Substance Use Disorder in Nursing*. Chicago: NCSBN. <https://www.ncsbn.org/nursing-regulation/practice/substance-use-disorder/substance-use-in-nursing.page>
4. Pew Charitable Trusts (2020, December 17). *Medications for opioid use disorder improve patient outcomes*. <https://www.pewtrusts.org/en/research-and-analysis/fact-sheets/2020/12/medications-for-opioid-use-disorder-improve-patient-outcomes>
5. S.445 - 117th Congress (2021-2022): Mainstreaming Addiction Treatment Act of 2021 (2021, February 25). <https://www.congress.gov/bill/117th-congress/senate-bill/445>
6. S.524 - 114th Congress (2015-2016): Comprehensive Addiction and Recovery Act of 2016. (2016, July 22). <https://www.congress.gov/bill/114th-congress/senate-bill/524>

## **Free resources and review course from Boston Medical Center Grayken Center for Addiction Training and Technical Assistance**

- [\*Addictions Nursing Certification Review: Practice Question Supplement for the CARN and CARN-AP Examinations\*](#)
- [\*Review Course & Test Taking Strategies courses are posted monthly for registration\*](#)
- [\*CARN/CARN-AP Exam Resources\*](#)
- [\*Upcoming Live Trainings\*](#)
- [\*Provider Resources\*](#)
- [\*OBAT Clinical Tools & Forms\*](#)
- [\*Extended-Release Buprenorphine Resources\*](#)

## **Clinical Guidelines**

- [\*Addiction Nursing Competencies: A Comprehensive Toolkit for the Addictions Nurse\*](#)
- [\*Buprenorphine Extended-Release Implementation Guide\*](#)
- [\*2021 Boston Medical Center OBAT Clinical Guidelines\*](#)

- [Boston Medical Center Project RESPECT Guidelines for Treating Opioid Use Disorder in Pregnant and Parenting Patients](#)

## **Free Clinical Decision-Making Application for web browser, iOS & Android**

- [MAT Quickstart App](#)

### **Journal Articles**

1. American College of Obstetricians and Gynecologists (2020). Tobacco and nicotine cessation during pregnancy: ACOG committee opinion, number 807. *Obstetrics and Gynecology*, 135(5), e221–e229. <https://doi.org/10.1097/AOG.0000000000003822>
2. American Society of Addiction Medicine (2020). The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. *Journal of Addiction Medicine*, 14(2S Suppl 1), 1–91. <https://doi.org/10.1097/ADM.0000000000000633>
3. Argyriou, E., Bakoyannis, G., Wu, W., Rattermann, M. J., & Cyders, M. A. (2023). Individual factors predict substance use treatment course patterns among patients in community-based substance use disorder treatment. *PLOS ONE*, 18(1), e0280407. <https://doi.org/10.1371/journal.pone.0280407>
4. Arhin, M., Mobley, J., Hamad, H., & Remick, P. (2023). Successful management of kratom use disorder with buprenorphine and naloxone. *Cureus*, 15(6), e41146. <https://doi.org/10.7759/cureus.41146>
5. Bommersbach, T. J., Rosenheck, R. A., & Rhee, T. G. (2022). National trends of mental health care among US adults who attempted suicide in the past 12 months. *JAMA Psychiatry*, 79(3), 219–231. <https://doi.org/10.1001/jamapsychiatry.2021.3958>
6. Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022). Novel agents for the pharmacological treatment of alcohol use disorder. *Drugs*, 82(3), 251–274. <https://doi.org/10.1007/s40265-021-01670-3>
7. Carpenter, M. J., Baker, N. L., Gray, K. M., & Upadhyaya, H. P. (2010). Assessment of nicotine dependence among adolescent and young adult smokers: A comparison of measures. *Addictive Behaviors*, 35(11), 977–982. <https://doi.org/10.1016/j.addbeh.2010.06.013>
8. Chokhawala, K., & Stevens, L. (2023, February 26). Antipsychotic medications. In *StatPearls*. <https://www.ncbi.nlm.nih.gov/books/NBK519503/>
9. Chu, A., & Wadhwa, R. (2023, May 1). Selective serotonin reuptake inhibitors. In *StatPearls*. StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK554406/>

10. Cunningham, S. D., Sutherland, R. A., Yee, C. W., Thomas, J. L., Monin, J. K., Ickovics, J. R., & Lewis, J. B. (2021). Group medical care: A systematic review of health service performance. *International Journal of Environmental Research and Public Health*, 18(23), 12726. <https://doi.org/10.3390/ijerph182312726>
11. De Crescenzo, F., Ciabattini, M., D'Alò, G. L., De Giorgi, R., Del Giovane, C., Cassar, C., Janiri, L., Clark, N., Ostacher, M. J., & Cipriani, A. (2018). Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: A systematic review and network meta-analysis. *PLOS Medicine*, 15(12), e1002715. <https://doi.org/10.1371/journal.pmed.1002715>
12. Earnshaw, V. A. (2020). Stigma and substance use disorders: A clinical, research, and advocacy agenda. *The American Psychologist*, 75(9), 1300–1311. <https://doi.org/10.1037/amp0000744>
13. Fischer, B., Robinson, T., Bullen, C., Curran, V., Jutras-Aswad, D., Medina-Mora, M. E., Pacula, R. L., Rehm, J., Room, R., van den Brink, W., & Hall, W. (2022). Lower-risk cannabis use guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update. *The International Journal on Drug Policy*, 99, 103381. <https://doi.org/10.1016/j.drugpo.2021.103381>
14. Fluyau, D., Mitra, P., & Lorthe, K. (2019). Antipsychotics for amphetamine psychosis: A systematic review. *Frontiers in Psychiatry*, 10, 740. <https://doi.org/10.3389/fpsyg.2019.00740>
15. Guenzel, N., & McChargue, D. (2023). Addiction relapse prevention. In *StatPearls*. StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK551500/>
16. Haskell, B. (2022). Identification and evidence-based treatment of post-acute withdrawal syndrome. *The Journal for Nurse Practitioners*, 18(3), 272-275. <https://doi.org/10.1016/j.nurpra.2021.12.021>
17. Jain, A., & Yilanli, M. (2023). Bulimia nervosa. In *StatPearls*. StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK562178/>
18. Jazaeri, S. A., & Habil, M. H. (2012). Reviewing two types of addiction - pathological gambling and substance use. *Indian Journal of Psychological Medicine*, 34(1), 5–11. <https://doi.org/10.4103/0253-7176.96147>
19. Kang, M., Galuska, M. A., & Ghassemzadeh, S. (2023, June 26). Benzodiazepine Toxicity. In: *StatPearls*. StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK482238/>
20. Kelly, J. F., Abry, A., Ferri, M., & Humphreys, K. (2020). Alcoholics Anonymous and 12-Step Facilitation treatments for alcohol use disorder: A distillation of a 2020 Cochrane Review for

clinicians and policy makers. *Alcohol and Alcoholism*, 55(6), 641–651.  
<https://doi.org/10.1093/alc/aga050>

21. Kumar, S., Srivastava, M., Srivastava, M., Yadav, J. S., & Prakash, S. (2021). Effect of motivational enhancement therapy (MET) on the self efficacy of individuals of alcohol dependence. *Journal of Family Medicine and Primary Care*, 10(1), 367–372.  
[https://doi.org/10.4103/jfmpc.jfmpc\\_1578\\_20](https://doi.org/10.4103/jfmpc.jfmpc_1578_20)
22. Lew-Starowicz, M., Lewczuk, K., Nowakowska, I., Kraus, S., & Gola, M. (2020). Compulsive sexual behavior and dysregulation of emotion. *Sexual Medicine Reviews*, 8(2), 191–205.  
<https://doi.org/10.1016/j.sxmr.2019.10.003>
23. Leza, L., Siria, S., López-Goñi, J. J., & Fernández-Montalvo, J. (2021). Adverse childhood experiences (ACEs) and substance use disorder (SUD): A scoping review. *Drug and Alcohol Dependence*, 221, 108563. <https://doi.org/10.1016/j.drugalcdep.2021.108563>
24. Maraz, A., & Yi, S. (2022). Compulsive buying gradually increased during the first six months of the Covid-19 outbreak. *Journal of Behavioral Addictions*, 11(1), 88–101.  
<https://doi.org/10.1556/2006.2022.00002>
25. Mestre-Bach, G., & Potenza, M. N. (2024). Pharmacological management of gambling disorder: An update of the literature. *Expert Review of Neurotherapeutics*, 24(4), 391–407.  
<https://doi.org/10.1080/14737175.2024.2316833>
26. McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kleber, H. D. (2000). Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. *JAMA*, 284(13), 1689–1695. <https://doi.org/10.1001/jama.284.13.1689>
27. Moraczewski, J., Awosika, A. O., & Aedma, K. K. (2023, August 17). Tricyclic antidepressants. In *StatPearls*. StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK557791/>
28. Morais, A. P. D., Pita, I. R., Fontes-Ribeiro, C. A., & Pereira, F. C. (2018). The neurobiological mechanisms of physical exercise in methamphetamine addiction. *CNS Neuroscience & Therapeutics*, 24(2), 85–97. <https://doi.org/10.1111/cn.12788>
29. Nasser, A. F., Heidbreder, C., Gomeni, R., Fudala, P. J., Zheng, B., & Greenwald, M. K. (2014). A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence. *Clinical Pharmacokinetics*, 53(9), 813–824. <https://doi.org/10.1007/s40262-014-0155-0>
30. Nawi, A. M., Ismail, R., Ibrahim, F., Hassan, M. R., Manaf, M. R. A., Amit, N., Ibrahim, N., & Shafurdin, N. S. (2021). Risk and protective factors of drug abuse among adolescents: A systematic review. *BMC Public Health*, 21(1), 2088. <https://doi.org/10.1186/s12889-021-11906-2>

31. Paulus, M. P., & Stewart, J. L. (2020). Neurobiology, clinical presentation, and treatment of methamphetamine use disorder: A review. *JAMA Psychiatry*, 77(9), 959–966.  
<https://doi.org/10.1001/jamapsychiatry.2020.0246>
32. Pergolizzi, J., Breve, F., Magnusson, P., LeQuang, J. A. K., & Varrassi, G. (2022). Cocaethylene: When cocaine and alcohol are taken together. *Cureus*, 14(2), e22498.  
<https://doi.org/10.7759/cureus.22498>
33. Potenza, M. N. (2017). Clinical neuropsychiatric considerations regarding nonsubstance or behavioral addictions. *Dialogues in Clinical Neuroscience*, 19(3), 281–291.  
<https://doi.org/10.31887/DCNS.2017.19.3/mpotenza>
34. Quiñones, A. R., Richardson, J., Freeman, M., Fu, R., O’Neil, M. E., Motu’apuaka, M., & Kansagara, D. (2014). Educational group visits for the management of chronic health conditions: A systematic review. *Patient Education and Counseling*, 95(1), 3–29. <https://doi.org/10.1016/j.pec.2013.12.021>
35. Resmark, G., Herpertz, S., Herpertz-Dahlmann, B., & Zeeck, A. (2019). Treatment of anorexia nervosa-new evidence-based guidelines. *Journal of Clinical Medicine*, 8(2), 153.  
<https://doi.org/10.3390/jcm8020153>
36. Saffaei, D., Lovett, S., & Rech, M. A. (2020). New-onset seizure in patient medicated with bupropion for smoking cessation: A case report. *The Journal of Emergency Medicine*, 58(3), e145–e147. <https://doi.org/10.1016/j.jemermed.2019.12.020>
37. Sajadi-Ernazarova, K.R., Anderson, J., Dhakal, A., & Hamilton, R.J. (2023, August 8). Caffeine withdrawal. In: *StatPearls*. StatPearls Publishing.  
<https://www.ncbi.nlm.nih.gov/books/NBK430790/>
38. Saref, A., Suraya, S., Singh, D., Grundmann, O., Narayanan, S., Swogger, M. T., Prozialeck, W. C., Boyer, E., Chear, N. J. Y., & Balasingam, V. (2019). Self-reported prevalence and severity of opioid and kratom (*Mitragyna speciosa* korth.) side effects. *Journal of Ethnopharmacology*, 238, 111876. <https://doi.org/10.1016/j.jep.2019.111876>
39. Scarth, M., Havnes, I. A., Jørstad, M. L., McVeigh, J., Van Hout, M. C., Westlye, L. T., Torgersen, S., & Bjørnebekk, A. (2022). Severity of anabolic steroid dependence, executive function, and personality traits in substance use disorder patients in Norway. *Drug and Alcohol Dependence*, 231, 109275. <https://doi.org/10.1016/j.drugalcdep.2022.109275>
40. Scholz-Hehn, A. D., Milin, S., Schulte, B., Reimer, J., Buth, S., & Schäfer, I. (2022). Substance use and chemsex in MSM - A latent class analysis. *Journal of Drug Issues*, 52(1), 83–96. <https://doi.org/10.1177/00220426211040564>
41. Sokol, R., Albanese, M., Chew, A., Early, J., Grossman, E., Roll, D., Sawin, G., Wu, D. J., & Schuman-Olivier, Z. (2019). Building a Group-Based Opioid Treatment (GBOT) blueprint: A qualitative study delineating GBOT implementation. *Addiction Science & Clinical Practice*, 14(1), 47. <https://doi.org/10.1186/s13722-019-0176-y>

42. Sorensen, C. J., DeSanto, K., Borgelt, L., Phillips, K. T., & Monte, A. A. (2017). Cannabinoid hyperemesis syndrome: Diagnosis, pathophysiology, and treatment-a systematic review. *Journal of Medical Toxicology*, 13(1), 71–87. <https://doi.org/10.1007/s13181-016-0595-z>
43. Soto, C., West, A. E., Ramos, G. G., & Unger, J. B. (2022). Substance and behavioral addictions among American Indian and Alaska Native populations. *International Journal of Environmental Research and Public Health*, 19(5), 2974. <https://doi.org/10.3390/ijerph19052974>
44. Srivastava, A. B., Mariani, J. J., & Levin, F. R. (2020). New directions in the treatment of opioid withdrawal. *Lancet*, 395(10241), 1938–1948. [https://doi.org/10.1016/S0140-6736\(20\)30852-7](https://doi.org/10.1016/S0140-6736(20)30852-7)
45. Stein, M. D., Conti, M. T., Kenney, S., Anderson, B. J., Flori, J. N., Risi, M. M., & Bailey, G. L. (2017). Adverse childhood experience effects on opioid use initiation, injection drug use, and overdose among persons with opioid use disorder. *Drug and Alcohol Dependence*, 179, 325–329. <https://doi.org/10.1016/j.drugalcdep.2017.07.007>
46. Swogger, M. T., Smith, K. E., Garcia-Romeu, A., Grundmann, O., Veltre, C. A., Henningfield, J. E., & Busch, L. Y. (2022). Understanding kratom use: A guide for healthcare providers. *Frontiers in Pharmacology*, 13, 801855. <https://doi.org/10.3389/fphar.2022.801855>
47. Telzer, E. H. (2016). Dopaminergic reward sensitivity can promote adolescent health: A new perspective on the mechanism of ventral striatum activation. *Developmental Cognitive Neuroscience*, 17, 57–67. <https://doi.org/10.1016/j.dcn.2015.10.010>
48. Topino, E., Cacioppo, M., & Gori, A. (2022). The relationship between attachment styles and compulsive online shopping: The mediating roles of family functioning patterns. *International Journal of Environmental Research and Public Health*, 19(13), 8162. <https://doi.org/10.3390/ijerph19138162>
49. Turner, A.R., Spurling, B.C., & Agrawal, S. (2023, July 31). Marijuana toxicity. In *StatPearls*. StatPearls Publishing. <http://www.ncbi.nlm.nih.gov/books/NBK430823/>
50. Varkey, B. (2021). Principles of clinical ethics and their application to practice. *Medical Principles and Practice*, 30(1), 17–28. <https://doi.org/10.1159/000509119>
51. Volkow N. (2020, April 22). *Addressing the stigma that surrounds addiction*. National Institute on Drug Abuse. Retrieved February 5, 2023, from <https://nida.nih.gov/about-nida/noras-blog/2020/04/addressing-stigma-surrounds-addiction>
52. Volkow, N. D., Koob, G. F., & McLellan, A. T. (2016). Neurobiologic advances from the brain disease model of addiction. *The New England Journal of Medicine*, 374(4), 363–371. <https://doi.org/10.1056/NEJMra1511480>
53. Wakeman, S. E., Larochelle, M. R., Ameli, O., Chaisson, C. E., McPheeters, J. T., Crown, W. H., Azocar, F., & Sanghavi, D. M. (2020). Comparative effectiveness of different treatment pathways for opioid use disorder. *JAMA Network Open*, 3(2), e1920622. <https://doi.org/10.1001/jamanetworkopen.2019.20622>

54. Wason, K., Potter, A., Alves, J., Loukas, V. L., Lastimoso, C., Sodder, S., Caputo, A., & LaBelle, C. T. (2021). Addiction Nursing Competencies: A Comprehensive Toolkit for the Addictions Nurse. *JONA: The Journal of Nursing Administration*, 51(9), 424–429. <https://doi.org/10.1097/NNA.0000000000001041>
55. Watts, S. A., Noble, S. L., Smith, P. O., & Disco, M. (2002). First-line pharmacotherapy for tobacco use and dependence. *The Journal of the American Board of Family Practice*, 15(6), 489–497.
56. Wesson, D. R., & Ling, W. (2003). The clinical opiate withdrawal scale (COWS). *Journal of Psychoactive Drugs*, 35(2), 253–259. <https://doi.org/10.1080/02791072.2003.10400007>
57. Wilens, T. E., & Morrison, N. R. (2012). Substance-use disorders in adolescents and adults with ADHD: Focus on treatment. *Neuropsychiatry*, 2(4), 301–312. <https://doi.org/10.2217/npy.12.39>
58. Wise, R. A., & Koob, G. F. (2014). The development and maintenance of drug addiction. *Neuropsychopharmacology*, 39(2), 254–262. <https://doi.org/10.1038/npp.2013.261>
59. Wolfe, B. E., Dunne, J. P., & Kells, M. R. (2016). Nursing care considerations for the hospitalized patient with an eating disorder. *The Nursing Clinics of North America*, 51(2), 213–235. <https://doi.org/10.1016/j.cnur.2016.01.006>